

# Κωνσταντίνος Πολυχρονάκος

## Βιογραφικό Σημείωμα

Ημερομηνία γέννησης 18 Απριλίου 1948

Τόπος γέννησης Έδεσσα

Υπηκοότητα Ελληνική και Καναδική

Διεύθυνση Montreal Children's Hospital

C-244 – 2300 Tupper Street

Montréal, Québec, H3H 1P3

Τηλ. 001 514 412 4400

Ηλεκτρονική διεύθυνση [constantin.polychronakos@mcgill.ca](mailto:constantin.polychronakos@mcgill.ca)

Τόπος Ιντερνετ <http://www.montreal-diabetes-research-center.org>

Πανεπιστημική μόρφωση Πτυχείο Ιατρικής Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης  
1972

### ΜΕΤΑΠΤΥΧΕΙΑΚΕΣ ΣΠΟΥΔΕΣ (Καναδάς)

1972-73	Rotating Internship, Πανεπιστήμιο Μανιτόμπας
1973-74	Ειδείκευση στην Παιδιατρική, Πανεπιστήμιο Μανιτόμπας
1974-75	Ειδίκευση στην Εργαστηριακή Ιατρική, Πανεπιστήμιο Οττάβας
1975-77	Ειδίκευση στην Παιδιατρική Πανεπιστήμιο Dalhousie
1977-79	Ειδίκευση στην Παιδιατρική Ενδοκρινολογία, Πανεπιστήμιο του Μοντρεάλ (Hôpital Ste Justine)
1980-83	Research fellow, Πανεπιστήμιο McGill (Polypeptide Hormone Laboratory and Montreal Children's Hospital)

### ΑΚΑΔΗΜΑΪΚΕΣ ΘΕΣΕΙΣ

1979-80	Research Associate, Πανεπιστήμιο του Montreal
1983-89	Assistant Professor, Τομέας Παιδιατρικής, πανεπιστήμιο McGill
1989-2000	Associate Professor, Τομέας Παιδιατρικής, πανεπιστήμιο McGill
2000-	Professor Τομέας Παιδιατρικής, πανεπιστήμιο McGill
1991-	Associate Member, Experimental Medicine, McGill
1997-	Associate Member, Τομέας Ανθρώπινης Γενετικής, McGill

### ΝΟΣΟΚΟΜΕΙΑΚΕΣ ΘΕΣΕΙΣ

1983-	Ενδοκρινολόγος πλήρους απασχόλησης, Montreal Children's Hospital
1998-	Διευθυντής Τμήματος Ενδοκρινολογίας, Montreal Children's Hospital
1997-	Διευθυντής, Endocrine Genetics Laboratory, Ερευνικτό Ινστιτούτο, Montreal Children's Hospital

## ΙΑΤΡΙΚΗ ΕΙΔΙΚΟΤΗΤΑ

1977	Παιδιατρική The Royal College of Physicians of Canada
1978	Παιδιατρική (College des Medecins du Québec)
1979	Ενδοκρινολογία (College des Medecins du Québec)

## ΥΠΟΤΡΟΦΙΕΣ ΚΑΙ ΔΙΑΚΡΙΣΕΙΣ

<b>1966-1972</b>	<b>Υποτροφία IKY</b> , 12.000 Δραχμές τον χρόνο
<b>1981 – 1983</b>	<b>Υποτροφία εκπαίδευσης στην έρευνα</b> (Research fellowship) Medical Research Council of Canada
<b>1983 – 1985</b>	<b>Junior Scientist Award</b> Montreal Children's Hospital Research Institute
<b>2005</b>	<b>Βραβείο Excellence in Research</b> Montreal Children's Hospital Foundation
<b>2008-2013</b>	<b>Βραβείο Sessenwein:</b> Montreal Children's Hospital Foundation \$39,000 ανα χρόνο, για 5 χρόνια
<b>2008</b>	<b>Βραβείο Ερευνητή καρριέρας</b> Fondation de la Recherche sur les Maladies Infantiles
<b>2009</b>	<b>Βραβείο Ερευνητή</b> Καναδική Παιδιατρική Εταιρία

## ΕΥΡΕΣΙΤΕΧΝΙΕΣ

1. DNA Assay for the Prediction of Autoimmune Diabetes, U.S. Patent No. 6,534,272 B2, July 23, 2001; **Lead Inventor Dr. Constantin Polychronakos**, Co-inventors: Dr. Petros Vafiadis, Rosemarie Grabs, and Dr. Houria Ounissi-Benkalha
2. Genetic Predictors of Risk for Type 2 Diabetes Mellitus. Patent Application filed. **Lead Inventor: C. Polychronakos.** Co-inventors: Robert Sladek and Philippe Froguel.
3. United States patent application 12/531,272; Inventors: Hakon Hakonarson, Struan F.A. Grant, Jonathan P. Bradfield, **Constantin Polychronakos**; Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes.
4. European National phase application of PCT/US2008/056869; Inventors: Hakon Hakonarson, Struan F.A. Grant, Jonathan P. Bradfield, **Constantin Polychronakos**; Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes.
5. United States patent application 12/531,257; Inventors: Hakon Hakonarson, Struan F.A. Grant, Jonathan P. Bradfield, **Constantin Polychronakos**; Genetic Alterations on

Chromosome 12 and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes.

6. European National phase application of PCT/US2008/56864; Inventors: Hakon Hakonarson, Struan F.A. Grant, Jonathan P. Bradfield, **Constantin Polychronakos**; Genetic Alterations on Chromosome 12 and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes.
7. International patent application PCT/US2009/044356; Inventors: Hakon Hakonarson, Struan F.A. Grant, Jonathan P. Bradfield, **Constantin Polychronakos**, Hui-Qi Qu; Gene tic alterations on Chromosomes 21q, 6q and 15q and Methods of Use of Thereof for the Diagnosis and Treatment of Type I Diabetes.

### ΜΕΤΑΠΤΥΧΙΑΚΗ ΕΠΙΤΗΡΗΣΗ ΚΑΙ ΔΙΔΑΣΚΑΛΙΑ

ΜΕΤΑΠΤΥΧΙΑΚΟΣ ΦΟΙΤΗΤΗΣ	ΧΡΟΝΟΛΟΓΙΑ	ΧΡΗΜΑΤΟΔΟΤΗΣΗ
<b>Nick Giannoukakis</b> Ph.D. Program, Anatomy and Cell Biology PhD obtained May 1997 <b>Genetic and epigenetic control of <i>IGF2</i> transcription</b>	1992-1997	FCAR
<b>Petros Vafiadis</b> Ph.D. Program Experimental Medicine PhD 1998 (Dean's list), Oelbaum award from JDRF) <b>Functional evaluation of the <i>IDDM2</i> locus</b>	1995-98	MRC doctoral scholarship
<b>Jean-Pierre Cloarec</b> Ph.D. Program, École Centrale de Lyon <b>Mésures d'impédance électrique pour l détection des séquences spécifiques d'ADN.</b>  Συν-επιτήρηση για περίοδο 18 μηνών εκπαίδευση στο εργαστήριο μου Διδακτορικό δίπλωμα από την École Centrale de Lyon	1997	Υποτροφία από Γαλλία
<b>Jennifer McCann</b> Ph.D. Program Experimental Medicine  <b>Genetic control of transcription of the human <i>IGF2R</i> gene</b>	1998-2003	Υποτροφία Liver Foundation
<b>Suzanne Anjos</b> Ph.D. program Department of Human Genetics  <b>The human cytotoxic T-lymphocyte antigen-4: functional significance of a signal peptide polymorphism associated with autoimmune endocrinopathies</b>	2000-02	Υποτροφία CIHR/Thyroid Foundation

<b>Michael Palumbo</b> Ph.D. Program Department of Experimental Medicine <b>Insulin expressing cells in the thymus</b>	2000-2002	Canadian Diabetes Association
<b>Mary Demian</b> Program Initiative Department of Human Genetics <b>Parent-of-Origin bias in IGF2R-LOH in breast cancer</b>	2001-2002	Canadian Breast Cancer Research
<b>Dina Levi</b> M.Sc., Department of Human Genetics  <b>Proinsulin-producing medullary thymic epithelial clones.</b>	2004 -	MCH-RI studentship award
<b>Yang Lu</b> M.Sc. Human Genetics <b>Effects of common sequence variants on mRNA translational efficiency</b>	2006	Genome Canada
<b>Hana Zouk</b> Ph D – Human Genetics  <b>Mechanisms of novel susceptibility loci for type 1 diabetes</b>	2006 -	Fonds de la Recherche en Santé du Québec
<b>Xiaoyu Du</b> Experimental Medicine <b>The role of <i>Plagl1</i> in β-cell development and function</b>	2004-	Pollack Fund

## Επιτήρηση Μεταδιδακτορικών Ερευνητών

Όνομα	περίοδος	Αντικείμενο	χρηματοδότηση
<b>Colm Costigan</b>	1983-84	IGF-II receptors in growth hormone deficiency	The MCH Research Institute
<b>Asterios Kukuvitis</b>	1993-95	Molecular genetics of diabetes and hypoglycemia	Alan Ross Academic Fellowship (McGill U)
<b>Robert Barnes</b>	1996-98	Physical mapping of the <i>IDDM12</i> locus	Canadian Diabetes Association
<b>Suzanne Demczuk</b>	1997-99	Transcript mapping and epigenetic modifications in the DiGeorge syndrome critical region	National Research Council (recipient of the prestigious H.L. Holmes award)
<b>Aziz Alami Chentoufi</b>	1999-2002	Thymic insulin expression in diabetes autoimmunity	Canadian Diabetes Association
<b>Mimi Kim, M.D.</b>	2004-	Regulatory T-cells in type 1 JDRF grant	

	2005	diabetes	
<b>Miranda Nakhla</b>	2004-2006	Immunogenetics of Type 1 Genetics	Eli Lily Canada Inc. – Canadian Pediatric Endocrinology Fellowship
<b>Brandy Wicklow</b>	2006-2008	Functional Evaluation of diabetes-associated Nonsynonymous polymorphism of the ALCAM gene	Eli Lily Canada Inc. – Canadian Pediatric Endocrinology Fellowship
	2008-2009	The Role of pancreatic Steatosis in the Pathology and Progression of Type 2 Diabetes in Adolescents	Manitoba Health Research Council for a Clinical Research Award
<b>Ghislain Rocheleau</b>	2005-2007	Analysis of genotyping and expression microarray data for Type 2 diabetes.	Genome Canada grant
<b>Julien Saint-Jean PhD</b>	2007-	Transcriptional regulators of insulin in the thymus: a whole-transcriptome approach	FRSQ fellowship
<b>Nadine Taleb, M.D.</b>	2007-	Homozygosity mapping of rare diabetes syndromes	MCH-RI fellowship (ranked #1 in the evaluation)
<b>Hugues Beauchemin, PhD</b>	2007-	A mouse model for human diabetes-associated polymorphisms	MCH RI fellowship
<b>Xiuying Yang, PhD</b>	2008-	High Throughput drug screening for modulating thymic insulin expression.	MDEIE grant (Québec-China)
<b>Hui Qi Qu MD, PhD</b>	2003-2009	Genomics of type 1 diabetes	CIHR fellowship
<b>Quan Li, PhD</b>	2009-	Susceptibility loci for Type 1 diabetes (T1D)	JDRF grant

## Διοικητικά καθήκοντα

### **Ερευνητικό Ινστιτούτο του *Montreal Children's Hospital***

1995 - 2009 Επιτροπή Fellowship του Ερευνητικού Ινστιτούτου (πρόεδρος 1998-2007)  
2009- Επιτροπή Υποτροφιών σε μεταπτυχιακούς

### **Ερευνητικό Ινστιτούτο του *McGill University Health Center***

2001 – 2008 Αντιπρόεδρος, *Research Council*  
1998 - 2008 Ηγέτης *Αξονας Ενδοκρινολογίας*  
2001 - 2008 Μέλος του *Management committee*

### **Royal College of Physicians of Canada**

1996 - 2000 Μέλος της επιτροπής-πυρήνα Ενδοκρινολογίας

## Αξιολογήσεις (Peer review)

*Journal of Medical Genetics* (IF=5.7).

Αρχισυντάκτης (Editor-in-Chief):  
Associate Editor, 2006- 2009

Editorial board: *Hormones, Archives de Pédiatrie, Clinical and Investigative Medicine*

Τακτικές αξιολογήσεις άρθρων για το *Nature Genetics, Diabetes, Diabetes Care, J Clin Endocrinol Metab* και πολλά άλλα.

Τέσσερις αξιολογήσεις για το *Science* και τρείς for *Nature* in 2007-09.

## Χρηματοδότηση Έρευνας

### **Στο παρελθόν**

<i>Medical Research Council of Canada</i>	The physiology of the receptors for insulin and insulin-like growth factors	\$36,000/ year \$35,000/ year \$21,372 for 9 months	1984-1986 1986-1988 1988-1989
<i>Montreal Children's Hospital Research Institute</i>	Interactions between mannose 6-phosphate and insulin-like growth factor II on their common receptor	\$38,000	1989-1990
<i>Cancer Research Society Inc</i>	Insulin-like growth factor receptors in human malignancy (in collaboration with M.N. Pollack, Lady Davis Institute)	\$35,000 /year \$35,000 /year	01/07/88 – 30/6/90 1990-1991
<i>Medical Research Council of Canada</i>	Interactions between mannose-6-phosphate and insulin-like factor II on their common receptor	\$45,000 /year	1990-1992
<i>Canadian Diabetes Association</i>	Insulin-like growth factor II in diabetes susceptibility	\$53,000	01/01/93 – 31/12/93
** <i>The Cancer Research Society Inc.</i>	Molecular genetics of Wilms' tumor	\$25,000 /year	01/07/93 – 30/06/95
** <i>The Hospital for Sick Children Foundation</i>	Candidate genes for Wilms' tumor	\$18,370 /year	01/10/93 – 30/09/95
** The above two grants constitute complementary funding for the same project.			
<i>Canadian Diabetes Association</i>	IGF2 as a susceptibility gene for insulin-dependent diabetes mellitus	\$51,120	01/01/94 – 31/12/94
<i>The National Research Council of Canada</i>	Transcript mapping and epigenetic changes in the DiGeorge syndrome critical region on chr. 22q11	\$100,000/year	01/09/97 – 31/08/99
(The HL Holmes award to my post-doctoral fellow Suzanne Demczuk, covering her salary and expenses.) <i>The Cancer Research Society Inc</i>	The IGF2R gene in Wilms tumor	\$45,000 /year	01/07/1995 – 30/06/1999

<i>The Cancer Research Society Inc.</i>	Allelic control of p73 transcription	\$49,000 /year	01/07/1999 – 30/06/2001
<i>Medical Research Council of Canada</i>	Parental imprinting of the genes for insulin-like growth factor II and its receptor	\$56,800 /year \$76,800 /year	01/04/1995 - 31/03/1998 01/04/1998 - 31/03/2002
<i>Juvenile Diabetes Foundation International</i>	Functional evaluation of the <i>IDDM2</i> locus	\$135,000 U.S. per year	01/09/1996 – 31/08/2003
<i>CIHR</i>	Direct detection of specific DNA sequences by electrochemical impedance measurements". Co-investigator with M. Lawrence (50% of budget to be spent in my lab).	\$45,300 /year	01/09/1997 – 30/09/2003
<i>Canadian Breast Cancer Research Institute</i>	Insulin-like growth factors and breast cancer: A Canadian research network"Co-investigator Dr. C.L. Deal	\$80,631 /year	07/2000-06/2003
<i>Réseau de recherche sur le développement, la santé et le bien-être de l'enfant</i>	Établissement d'une banque de donnée dynamique pour l'institution d'un réseau de traitement et de recherche en diabétologie pédiatrique" Co-investigators: Dr. L. Legault - McGill University, Dr. K. Khoury - Université de Sherbrooke, Dr. M. Lelièvre - Université Laval, and Dr. M. Buthieu - Université de Montréal	\$19,973 /year \$16,100 /year	01/04/2001 - 31/03/2002 01/04/2002 - 31/03/2003
<i>Canadian Diabetes Association</i>	Insulin expressing cells in the thymus	\$57,878 /year \$67,030 /year	01/07/2000 - 30/06/2002 01/07/2002 - 30/06/2004
<i>Juvenile Diabetes Research Foundation International</i>	A function-driven, large scale approach to the search for type 1 diabetes susceptibility genes	\$405,753 US / year	01/11/2001 - 31/10/2006
<i>Genome Canada II</i>	Functional genomics of type 1 diabetes. (PI Jayne Danska)	\$5,700,000/3 years Amount corresponding to my laboratory: \$975,000	01/09/2003 - 31/08/2006
<i>Juvenile Diabetes Research Foundation International</i>	Functional evaluation of IDDM Loci	\$135,852.46 U.S./ year	01/08/2003 - 31/07/2006
<i>Genome Canada (Genomics and Proteomics in Human Health RFA)</i>	Genetics of type 2 diabetes (PI Barry I. Posner)	\$16M 174,000/y to my lab +I am one of three individuals to manage the \$3M genotyping budget.	Fall 2004-2007
<i>National Institute of Health (NIH) (USA) via George Washington University Juvenile Diabetes Research Foundation</i>	TrialNet Major Affiliate Functional Evaluation of IDDM Loci	\$269,242.00 \$159,912.70 Yearly	05-2006 to 06/2008 11/2006 to 08/2009
<i>Juvenile Diabetes Research Foundation</i>	A novel gene necessary for the development of the Endocrine Pancreas	\$271,368. over 2 years	09/2007 to 08/2009

## Τρέχουσα χρηματοδότηση

<b>Πηγή</b>	<b>Αντικείμενο</b>	<b>Ποσό</b>	<b>διάρκεια</b>
<i>JDRF</i>	Novel Genetic Susceptibility Loci for Type 1 Diabetes	494,835 over 3 years DECLINED (CIHR-funded)	June 1/2008 to May 31/2011
<i>CIHR</i>	Team in Immune Regulation and Biomarker Development for Pediatric and Adult Autoimmune Diseases Dr. Amit Bar-Or	\$2,018,445.00 (\$50,000 to my lab)	July 1/2007 to June 30, 2012
<i>Genome Canada / Genome Quebec</i>	Gene Regulators in Disease (GRID)	\$10.79M 432,100 / 4 yrs to my	01/2006 – 12/2009

(PI is T. Pastinen, after the  
departure of T.J. Hudson)

*Ministère du Développement  
économique, de l'innovation et  
l'Exportation (MDEIE).  
Québec-China*

Discovery of Novel Therapeutic  
for the Prevention of Type 1  
Diabetes.

\$150,000 CDN over 3 years

09/2008 to 08/2011

*JDRF*

Mechanisms involved in  
novel genetic associations  
with Type 1 diabetes

158,434 yearly

April 1, 2007 to March  
31, 2010

*CIHR*

Novel Genetic Susceptibility  
For Type 1 diabetes

\$147,062 yearly

October 1/2008-Sept  
30/2011

*Juvenile Diabetes Research  
Foundation – Biomarkers  
Autoimmunity  
PI: Ciro Piccirillo, M.D.*

Integrating genetics with markers  
of immune response

\$600,000 / 3 years

\$39,600 US yearly to

my lab

Sept 1, 2008 to August  
31/2011

*NIH*

Fine Mapping and Functional  
Evaluation of Selected Type  
1 diabetes Loci

\$6,790,290 / 5 years

\$400,000 yearly

Sept 1, 2009 to Aug 31,  
2014

*CIHR-Training Grant*

From Population-based studies  
biology: a genetic epidemiolog  
Training program  
Co-applicant

04/2010 to 03/2015

*CIHR*

A genome-wide survey of the  
effect  
mRNA polymorphisms on  
translational efficiency

\$538,011

10/2000-09/2014  
PENDING

### Διαλέξεις σαν προσκεκλημένος ομιλητής

- 1 *Recepteurs de l'insuline et des IGF* St Justine Hospital, weekly research 1982
- 2 *Insulin receptor modulation* Grand Rounds, CHEO, Ottawa 1983
- 3, *Les IGF* Two one-hour lectures, part of the 1987, 1989,  
*Hormones peptidiques* course at Université 1991  
de Montréal
- 4,
- 5
- 6 *Les IGF et leurs récepteurs* Department of Pediatrics, Centre Hospitalier 1987  
Université Laval, Québec
- 7 *Les IGF dans le diabète et le cancer* St. François-d'Assise Hospital Research 1989  
Center

- 9 *Les IGF dans le diabète et le cancer* Hôpital Notre-Dame Research Center 1990  
Seminar series
- 10 *Disease self-management: diabetes as a model* European Society of Ambulatory Pediatrics. 1990  
Annual meeting, *Athens, Greece*
- 11 *Effector mechanisms of non-HLA genetic susceptibility to  $\beta$ -cell autoimmunity.* Gordon Research Conference, *Ventura Ca,* January 1997
- 12 *Off-label uses of growth hormone* Health Canada, Bureau of Drug Research March 1997  
Ottawa
- 13 *The genetics of type 1 diabetes: beyond HLA* Humatrop<sup>R</sup> symposium, Banff Alberta. February 1998  
Sponsored by *Eli Lilly*
- 14 *The IDDM2 locus: functional evaluation and parent-of-origin effects* Research Seminar, Children's Hospital of Philadelphia, *Dept. of Pediatrics, U of Pennsylvania* January 1998
- 15 *Mitochondrial Diabetes* Symposium: *The Molecular Basis of Diabetes Mellitus*, University of Athens, April 1998  
Greece
- 16 *Ριζική θεραπεία του διαβήτη τύπου 1 Πόσο μακριά είμαστε;* Το πρώτο συνέδριο της Ελληνικής Αμοστπονδίας διαβητικών April 1998
- 17 *Parental imprinting: relevance to human disease* Faculty of Medicine, University of Ioannina. April 1998  
Ioannina Greece. Sponsored by *Bayer*
- 18 *Functional Evaluation of the IDDM2 locus* Research Seminar, Department of Medicine, April 1998  
University of Ioannina, Greece. Sponsored by the *Hellenic Diabetes Federation*
- 19 *Genotype-dependent parent-of-origin effects* The Spring Meeting of the British Genetical Society, Warwick, England April 1998
- 20 *Genetic risk factors for insulin-dependent diabetes* NIH workshop on vaccines and autoimmune diabetes. *US National Institutes of Health, Bethesda MD* May 1998
- 21 *Genetic control of epigenetic* NIEH-sponsored symposium on Imprinting October 1998

	<i>modifications in imprinted genes</i>	and environmental disease susceptibility. <i>Duke University</i>	
22	<i>Functional evaluation of IDDM2 locus</i>	Schneider Children's Medical Center, Tel Aviv	March 1999
23	<i>Parental imprinting</i>	Schneider Children's Medical Center, Tel Aviv	March 1999
24	<i>Molecular endocrinology of cancer</i>	Annual Meeting of the Hellenic Endocrine Society	March 1999
25	<i>The IGF system in cancer</i>	Annual Meeting of the Hellenic Endocrine Society, Athens	March 1999
26	<i>The genetics of autoimmune diabetes: beyond HLA</i>	Dept. of Genetics, University of Manitoba	Feb. 2000
27	<i>The insulin VNTR in diabetes</i>	City-wide Endocrine Rounds, U of Toronto	Feb. 2000
28	<i>Viral infections in the etiology of autoimmune diabetes</i>	“Infection and chronic disease: strange bedfellows” Conference sponsored by the Canadian Public Health Alliance and Health Canada	May 2000
29	<i>Genetics of type 1 diabetes</i>	American University of Beirut, Dept. of Peds	Feb 2001
30	<i>Immunogenetics of diabetes</i>	University of Pittsburgh	March 2001
31	<i>The Human Genome Project: what is in it for the endocrinologist?</i>	Serono Symposium: Review of Pediatric Endocrinology	July 2001
32	<i>Immunogenetics of Diabetes</i>	Joint International Pediatric Endocrine Societies meeting, Montreal	July 2001
33	<i>Transient Neonatal Diabetes: a model of endocrine disease due to defects in parental imprinting</i>	The Annual Congress of the Italian Society for Pediatric Endocrinology, Trieste, Italy	October 2001
34	<i>Diabète type 1 génétique et génomique</i>	Réunion Scientifique de l'Hôpital Ste-Justine, Montréal, Québec	January 2002
35	<i>Parental genomic imprinting: Implications for health, disease and organism cloning</i>	Université de Montréal.	April 2003

36	<i>Genetic testing in Endocrine Research and Practice</i>	12 <sup>th</sup> Balkan Congress of Endocrinology, Thessaloniki Greece.	May 2003
37	<i>Newly discovered forms of Mendelian diabetes: insights and puzzles</i>	The Lawson Wilkins Pediatric Endocrine Society annual meeting, Seattle.	May 2003
38	<i>Insulin: expression in the thymus and T-cell self-tolerance</i>	Symposium talk at annual meeting of American Diabetes Association, New Orleans.	June 2003
39	<i>Genome Science and the Individual: lessons from type 1 diabetes</i>	The Harry Medovoy lectureship. Department of Pediatrics. University of Manitoba, Winnipeg	May 2004
40	<i>Genomics for the Endocrinologist</i>	2 <sup>nd</sup> International Conference on Adult consequences of Pediatric Disease. Ahtens, Greece.	May 2004
41	<i>Insulin: thymic hormone or thymic antigen?</i>	6th Symposium of the International Group on Insulin Secretion. St-Jean Cap Ferrat, France	March 2005
42	<i>Genetics of type 1 diabetes</i>	Biomedical Conference U of Ulm, Germany	Sept 2005
43	<i>Dissecting the genetic determinants of complex traits: lessons from diabetes</i>	Canadian Federation of Biological Societies U of Guelph,	June 2005
44	<i>Strand asymmetry in transcribed human sequences: evidence for functional effects</i>	<i>Human Genome Variation 2006</i> meeting, Hong Kong, China	Sept 2006
45	<i>La génétique du diabète type 1</i>	Université de Montréal (Centre de Recherche Guy Bernier) March 2006	March 2006
46	<i>Genetics of diabetes in the HapMap era</i>	Immunogenetics seminar, U Pittsburgh	Mar 2007
47	<i>Genetics of diabetes in the HapMap era</i>	Canadian Pediatric Endocrine Group Annual Meeting, London, Ontario	April 2007
48	<i>A genome-wide association study for type 1 diabetes</i>	Canadian Genetic Diseases Network Annual Meeting, St. Sauveur, Quebec	April 2007
49	<i>Genetics of diabetes in the HapMap era</i>	<i>Institute of Pharmacology, Chinese Academy of Medical Sciences, Beijing</i>	Apr 2007

50	<i>Insulin in the thymus: hormone or antigen?</i>	<i>Institute of Pharmacology, Chinese Academy of Medical Sciences, Beijing</i>	Apr 2007
51	<i>A Genome-wide View of Human Variation and Its use in Gaining Functional Insights: Diabetes as Paradigm</i>	Metabolomics Approach to Human Diseases. Genomics and Peptidomics. 13 <sup>th</sup> Samsung International Symposium on Molecular Medicine, Seoul, Korea,	Oct 2007
52	<i>Genes and Type 2 diabetes. How far is genetic prediction in children?</i>	33 <sup>rd</sup> Annual Meeting International Society for Pediatric and Adolescent Diabetes, Berlin, Germany.	Sept 2007
53	<i>The genetics of diabetes in the HapMap era</i>	Symposium talk at the Australian Diabetes Society (ADS) & the New Zealand Society for the Study of Diabetes Joint Scientific Meeting, Christchurch New Zealand.	Sept 2007
54	<i>Type 1 diabetes: from prediction to prevention</i>	Plenary talk at the Australian Diabetes Society (ADS) & the New Zealand Society for the Study of Diabetes Joint Scientific Meeting, Christchurch New Zealand.	Sept 2007
55	<i>What is new in the genetics of diabetes</i>	Westmead Children's Hospital, Sydney, Australia	Sept 2007
57	<i>Common and rare forms of diabetes: what can genetics teach us about the beta cell?</i>	Canadian Beta Cell Group annual meeting, Toronto	Nov 2007
58	<i>Recent progress in the genetics of diabetes</i>	City-wide Endocrine Rounds, Toronto	Nov 2007
59	<i>Recent breakthroughs in the genetics of diabetes</i>	Keynote address to the Annual Meeting, Diabetology Society of Northern Greece.	Nov 2007
60	<i>The genetics of type 1 diabetes: recent, past and the future</i>	Erasmus University, Rotterdam	Feb 11/2008
61	<i>The genetics of type 1 diabetes: recent past and the future</i>	University of Turku, Finland	Feb 2008
62	<i>Studies on the Genetics of T1D</i>	Joslin Diabetes Center, Harvard University, Boston	April 2008
63	<i>Genetics of type 1 diabetes: Where do we go from here?</i>	Beyond Genome: Genotyping and Large-Scale Association Studies Conference –	June 9-10/08

		Cambridge Healthtech Institute, San Francisco, California Session chair and speaker	
64	<i>The genetics of Diabetes</i>	University of Pittsburgh School of Medicine – Children's Hospital of Pittsburgh Molecular Medicine Research Seminar	March 2009
65	<i>Therapeutics Development for Personalized Medicine: What Have We Learned from Complex-trait Genetics</i>	BIT' 2nd World Congress of Industrial Biotechnology-2009, Seoul, Korea	April 2009
66	<i>The genetics of diabetes: where do we go from here?</i>	36 <sup>th</sup> Pahellenic Congress of Endocrinology and Metabolism, Alexandroupolis, Greece	April 2009
67	<i>Genome-Wide Studies on Type I diabetes</i>	Fourth Canadian Genetic Epidemiology and Statistical Genetics Meeting, Harrison Hot Springs, British Columbia	May 2009
68	<i>Genetic of Type 1 Diabetes</i>	American College of Veterinary Internal Medicine. Montreal	June 2009
69	<i>Copy-Number and other rare, highly penetrant variants: What is the Evidence?</i>	45 <sup>th</sup> Annual Meeting, European Association for the Study of Diabetes, Vienna – Type 1 Diabetes Genetics –Symposium	Sept 2009
70	<i>Where now for Diabetes Genetics?</i>	International Diabetes Federation 20 <sup>th</sup> World Diabetes Congress Montreal	Oct 18-22/2009
	<i>Genetics of diabetes and its complications</i>	New Trends In Diabetic Nephropathy – Thessaloniki, Greece	Oct 9-10/2009
71	<i>Genetics and the development of Type I diabetes</i>	Recent Advances in Beta-Cell Biology: Scientific and Clinical Implications, Toronto (IDF satellite)	Oct 16-17/2009
72	<i>Type 1 Diabetes-Life in the GWAS era</i>	CCMG Annual Scientific Meeting in Banff Alberta, Whole Genome Association Studies Symposium	Nov 2009

## Δημοσιεύσεις

### **Πρωτότυπα άρθρα (αστερίσκος = φοιτητής ή πρωσοπικό του εργαστηρίου μου)**

1. **Polychronakos C**, Letarte J, Collu R, Ducharme JR. Carbohydrate intolerance in children and adolescents with Turner's syndrome. *J Pediatr* 96:1009-1014, 1980.
2. Savoie S, **Polychronakos C**, Forest MG, Haour F, Collu R, Ducharme JR. Perinatal activity of the hypo-thalamic-pituitary-gonadal axis in the lamb. III. LH, testosterone and prolactin secretory pattern in newborn lambs. *Hormone Research* 1981, 15:167.
3. Hamel R, Forest MG, Haour F, **Polychronakos C**, Charpenet G, Gibb W, Collu R, Ducharme JR. Perinatal activity of the hypo-thalamic-pituitary-gonadal axis in the lamb. IV Testicular responsiveness to hCG from 1 through 28 days of life. *Hormone Research* 1981, 15:179.
4. **Polychronakos C**, Tsoukas G, Ducharme JR, Letarte J, Collu R. Gigantism and hyperprolactinemia in polyostotic fibrous dysplasia. *J Endocrinol Invest* 1982, 5:323.
5. **Polychronakos C**, Ruggere MD, Benjamin A, Posner BI, and Guyda H. The role of cell age in the difference in insulin binding between adult and cord erythrocytes. *J Clin Endocrinol Metab* 1982, 55:290.
6. **Polychronakos C**, Guyda HJ, Posner BI. Receptors for the insulin-like growth factors on human erythrocytes. *J Clin Endocrinol Metab* 1983, 57: 436.
7. Burnstein R, **Polychronakos C**, Toews CJ, McDougall JD, Guyda HJ, Posner BI. Acute reversal of the enhanced insulin action in trained athletes: Association with insulin receptor changes. *Diabetes* 1985, 34:756-760.
8. **Polychronakos C**, Guyda HJ, and Posner BI. Increase in type 2 insulin-like growth factor receptors in the rat kidney during compensatory growth. *Biochemical & Biophysical Research Communications* 1985, 132:418.
9. **Polychronakos C**, Guyda HJ, Patel B, and Posner BI. Increase in the number of insulin-like growth factor receptors during propyl-thiuracil-induced hyperplasia in the rat thyroid. *Endocrinology* 1986, 119:1204-1209.
10. Schiffrin A, **Polychronakos C**, \*Abu-Srair H. Glycogen storage disease Type I. [Letter reporting original observations] *N. Engl. J. Med.* 1986, 315(8): 520-521.
11. Desjardins JG, Khan AH, Montupet P, Collin PP, Leboeuf G, **Polychronakos C**, Simard P, Boisvert J, and Dube LJ. Management of thyroid nodules in children: a 20-year experience. *J of Pediatric Surgery*. 1987, 22(8): 736-739.

12. Barenton B, Guyda HJ, Goodyer C, **Polychronakos C**, Posner BI. Specificity of insulin-like growth factor binding to type II IGF receptors in rabbit mammary gland and hypophysectomized rat liver. *Biochemical and Biophysical Research Communications*. 1987, 149(2): 555-561.
13. \*Costigan CD, **Polychronakos C**, Guyda HJ, and Posner BI. Increase in specific binding of insulin-like growth factor (IGF) II to type I (IGF) receptors on erythrocytes of hypopituitary children receiving GH therapy. *Clin. Invest. Med.* 1988, 11(1): 47-51.
14. Pollak M, **Polychronakos C**, Yussefi S, Richard M. Characterizations of IGF-I receptors in the MCF-7 breast cancer cell line. *Biochem. Biophys. Res. Commun.* 1988, 154:326-331.
15. Belmonte MM, Schiffrin A, Dufresne J, Suissa S, Goldman H, **Polychronakos C**. Impact of home blood glucose monitoring on control of diabetes as measured by HbAl. A 3 year survey of a juvenile IDDM clinic. *Diabetes Care* 1988, 11: 484-488.
16. **Polychronakos C**, Piscina R. Endocytosis of receptor-bound IGF-II is enhanced by mannose-6-phosphate in IM9 cells. *Endocrinology* 1988, 123:2146.
17. **Polychronakos C**, Guyda H, \*Abu-Srair H. Transient growth deceleration in normal short children: a potential source of bias in growth studies. *European Journal of Pediatrics* 1988, 147:582-3.
18. **Polychronakos C**, Guyda HJ, Posner BI. Mannose-6-phosphate increases the affinity of its cation- independent receptor for insulin-like growth factor II by displacing inhibitory endogenous ligands. *Biochem. Biophys. Res. Commun.* 1988, 157:632.
19. **Polychronakos C**, Piscina R, Fantus IG. Enhancement of cytosolic tyrosine kinase activity by Propylthiouracil-induced hyperplasia in the rat thyroid. *Endocrinology* 1989, 124:505.
20. Pollak M, **Polychronakos C**, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. *Anticancer Research* 1989, 9:889-892.
21. Pollak MN, **Polychronakos C**, Richard M. Insulin-like growth factor - I: a potent mitogen for human osteogenic sarcoma. *Journal of the National Cancer Institute* 1990, 82(4):301-305.
22. **Polychronakos C**, Guyda HJ, Janthly U, Posner BI. Effects of mannose 6-phosphate on receptor-mediated endocytosis of IGF-II. *Endocrinology* 127:(4) 1990, 1861-1866.

23. Pollak M, **Polychronakos C**, \*Blauer S, Guyda H, Margolese R. Effect of tamoxifen on serum insulin-like growth factor-I levels of Stage I breast cancer patients. *J. Natl. Cancer Inst.* 1990, 82(21) 1693-1697.
24. **Polychronakos C**, Janthly U, Lehoux JC, Koutsilieris M. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. *The Prostate* 1991, 19:313-321.
25. Koutsilieris M, **Polychronakos C**. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. *Anticancer Research* 1992, 12:905-910.
26. \*Giannoukakis N, Deal C, Paquette J, Goodyer CG, **Polychronakos C**. Parental genomic imprinting of the human *IGF2* gene. *Nature Genetics* 1993, 4:98-101.
27. Koutsilieris M, Frenette G, Lazure C, Lehoux JC, Govindan MV, **Polychronakos C**. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. *Anticancer Research* 1993, 13:481-486.
28. \*Xu Y, Goodyer CG, Deal C, **Polychronakos C**. Functional polymorphism in the parental imprinting of the human *IGF2R* gene. *Biochemical and Biophysical Research Communications* 1993, 197:747-754.
29. **Polychronakos C**, Ligier S. Resuspension of intermediate-acting insulin as a source of error in insulin dosing. *Diabetes Care* 1994, 17:1234-1235.
30. **Polychronakos C**, Giannoukakis N, Kukuvitis A and E Colle. Parental imprinting effect at the *INS-IGF2* diabetes susceptibility locus. *Diabetologia*, 1995, 38(6):715-719.
31. \*Kukuvitis K, Matte C and C **Polychronakos**. Central precocious puberty following cure of a feminizing granulosa ovarian tumor. *Hormone Research*, 1995, 44:268-270.
32. **Polychronakos C**, Giannoukakis N and C Deal. Imprinting of *IGF2*, insulin-dependent diabetes, immune function and apoptosis: A Hypothesis. *Developmental Genetics* 1995, 17:253-62.
33. Treacy E, **Polychronakos C**, Vekemans M, Blaichman S, Xu Y and VM Der Kaloustian. De novo translocation between chromosomes 6 and 15 [45,XX,t(6;15)(q25;q11.2)] and further evidence of lack of imprinting of the insulin-like growth factor II/mannose-6- phosphate receptor. *Journal of Medical Genetics*, 1996, (33):42-46.
34. \*Giannoukakis N, Deal C, Paquette J, Kukuvitis A and C **Polychronakos**. Polymorphic functional imprinting of the human *IGF2* gene among individuals, in blood cells, is associated with *H19* expression. *Biochemical and Biophysical Research Communications*. 1996, 220(3):1014-1019.
35. \*Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG and C **Polychronakos**. Imprinted and genotype-specific expression of genes at the *IDDM2* locus in pancreas and leucocytes. *Journal of Autoimmunity*, 1996, 9:397-403.

36. Sourla A, **Polychronakos C**, Nepveu A, Kukuvitis A, Naud F and M Koutsilieris. Plasminogen activator inhibitor-1 mRNA and molecular evidence for del(7)q22 in uterine leiomyomas. *Cancer Research*, 1996, 56:3123-3128.
37. \*Wolanski R, Sigman T and **C Polychronakos**. Assessment of blood glucose self-monitoring skills in a camp for diabetic children: the effects of individualized feedback counselling. *Patient Education and Counselling* 1996, 29:5-11.
38. \*Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R\*, Goodyer, CG, Wickramasinghe S, Colle E and **C Polychronakos**. Insulin expression in human thymus is modulated by *INS* VNTR alleles at the *IDDM2* locus. *Nature Genetics* 1997, 15: 289-292.
39. \*Xu Y, Grundy P and **C Polychronakos**. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. *Oncogene* 1997, 14: 1041-1046.
40. \*Kukuvitis A, Arbour L, Deal C and **C Polychronakos**. An autosomal dominant form of familial persistent hyperinsulinemic hypoglycemia of infancy, not linked to the sulfonylurea receptor locus. *Journal of Clinical Endocrinology and Metabolism* 1997, 82: 1192-94.
41. Bennett ST, Wilson AJ, Esposito L, Bouzekri N, Undlien DE, Cucca F, Nistico L, Buzzetti R, the IMDIAB Group, Bosi E, Pociot F, Nerup, Cambon-Thomsen A, Pugliese A, Shield JPH, McKinney PA, Bain SC, **Polychronakos C** and JA Todd. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of the untransmitted paternal allele. *Nature Genetics*.1997, 17:350-52.
42. \*Xu YQ, Papageorgiou A and **C Polychronakos**. Developmental Regulation of the soluble form of the mannose 6-phosphate/IGF-II receptor in human serum and amniotic fluid. *Journal of Clinical Endocrinology and Metabolism*. 1998, 83: 437-442.
43. \*Vafiadis P, Grabs R, Goodyer CG, Colle E, and **C Polychronakos**. Functional analysis of the role of *IGF2* in *IDDM2*-encoded susceptibility to type 1 diabetes. *Diabetes* 1998, 47:831-46.

44. Paquette J, \*Giannoukakis N, **Polychronakos C**, \*Vafiadis P and C Deal. The insulin 5' VNTR is associated with *IGF2* expression in humans. *Journal of Biological Chemistry* 1998, 273:14158-64.
45. Riesewijk AM, \*Xu YQ, Schepens MT, Mariman EM, **Polychronakos C**, Ropers HH and V Kalscheuer. Absence of an obvious molecular imprinting mechanism in a human fetus with monoallelic *IGF2R* expression. *Biochem Biophys Res Commun.* 1998, Apr. 7, 245(1):272-7.
46. \*Mai M. Grabs R\*, Barnes RD, \*Vafiadis P and **C Polychronakos**. Shortened PCR cycles in a conventional thermal cycler. *BioTechniques* 1998, 25(2):208-209.
47. \*Vafiadis P, Bennett ST, Todd JA and **C Polychronakos**. Divergence between genetic determinants of *IGF2* transcription levels in leukocytes and of IDDM2-encoded susceptibility to type 1 diabetes. *J Clin Endocrinol Metab.* 1998, 83(8):2933-9, Aug .
48. \*Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick D, **Polychronakos C**, Smith DI and W Liu. Loss of imprinting and allele switching expression of p73 in renal cell carcinoma. *Oncogene*, 1998, 17(13):1739-1741.
49. \*Cloarec JP, Martin JR, **Polychronakos C**, Lawrence I, Lawrence MF and E Souteyrand. Functionnalization of Si/SiO<sub>2</sub> substrates with homooligonucleotides for a DNA biosensor. *Sensors and Actuators* 1999, B58: 394-398.
50. Gardner RJ, Mackay DJG, Mungall AJ, **Polychronakos C**, Siebert R, Shield JPH, Temple IK and DO Robinson. An imprinted locus associated with transient neonatal diabetes mellitus. *Human Molecular Genetics*, 2000, 9(4): 589-596.
51. \*Vafiadis P., Ounissi-Benkhala H., \*Palumbo M., Grabs R\*, Goodyer CG and **C Polychronakos**. Class III VNTR alleles associated with silencing of thymic insulin expression predispose to autoimmune diabetes. *J Clin Endocrinol Metab:* 2001, 86(8):3705-3710.
52. Merriman TR, Cordell HJ, Eaves IA, Danoy PA, Coraddu F, Barber R, Cucca F, Broadley S, Sawcer S, Compston A, Wordsworth P, Sharford J, Laval S, Jirholt J, Holmdahl R, Theofilopoulos AN, Kono DH, Tuomilehto J, Tuomilehto-Wolf E, Buzzetti R, Marrosu MG, Undlien DE, Ronningen KS, Ionesco-Tirgoviste C, Shield JP, Pociot F, Nerup J, Jacob CO, **Polychronakos C**, Bain SC and JA Todd. Suggestive evidence for association of human chromosome 18q12-q21 and its orthologue on rat and mouse chromosome 18 with several autoimmune diseases. *Diabetes* 2001, 50(1): 184-194.
53. Croteau S, **Polychronakos C** and A Naumova. Imprinting defects in mouse embryos: stochastic errors or polymorphic phenotype? *Genesis* 2001, 31:11-16.
54. \*McCann JA, Zheng H, Islam A, Goodyer CG and **C Polychronakos**. Evidence against *GRB10* as the gene for Silver-Russel Syndrome. *Biochemical and Biophysical Research Communications*, 2001, 286:943-8.
55. \*Cloarec JP, \*Deliganis N, Martin JR, Lawrence I, Souteyrand E, **Polychronakos C** and

- MF Lawrence. Immobilization of homooligonucleotide probe layers onto Si/SiO<sub>2</sub> substrates: Characterization by electrochemical impedance measurements and radiolabelling. *Biosensors and Bioelectronics* 2001, 17(5):405-412.
56. Marquette CA, Lawrence I, **Polychronakos C** and MF Lawrence. Impedance based DNA chip for direct  $T_m$  measurement. *Talanta* 2002, 56(4):763-768.
57. \*Alami Chentoufi A and **C Polychronakos**. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: The mechanism by which the IDDM2 locus may predispose to diabetes. *Diabetes* 2002, 51:1383-1390.
58. \*Zavalkoff SR and **C Polychronakos**. Evaluation of conventional blood glucose monitoring as an indicator of integrated glucose values using a continuous subcutaneous sensor. *Diabetes Care*, 2002, 25:1603-1606.
59. \*Anjos S, Nguyen A, \*Ounissi-Benkhala H, \*Tessier MC and **C Polychronakos**. A common autoimmunity predisposing a signal peptide variant of the cytotoxic T-lymphocyte antigen-4 results in inefficient glycosylation of the susceptibility allele. *Journal of Biological Chemistry*, 2002, 277(48):46478-46486.
60. **Polychronakos C** and A \*Kukuvitis. Parental genomic imprinting in endocrinopathies. *European Journal of Endocrinology* 2002, 147(5):561-569.
61. Ducharme FM, Chabot G, **Polychronakos C**, Glorieux F and B Mazer. Safety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density, and adrenal function. *Pediatrics* 2003, Feb;11(2):376-83.
62. \*Punthakee Z, Legault L and **C Polychronakos**. Prednisolone in the treatment of adrenal insufficiency: A reevaluation of relative potency. *J Pediatr*. 2003, Sep;143(3):402-5.
63. Macanovic A, Marquette C, **Polychronakos C** and MF Lawrence. Impedance-based detection of DNA sequences using a silicon transducer with PNA as the probe layer. *Nucleic Acids Research* 2004, Jan 22;32(2):E20.

64. \*Chentoufi A, \*Palumbo M and **C Polychronakos**. Proinsulin expression by Hassall's corpuscles in the mouse thymus. *Diabetes* 2004, 53(2):354-9.
65. \*Kukuvitis A, Georgiou I, Syrrou M, Andronikou S, Dickerman A, \*Islam A, \*McCann J and **C Polychronakos**. Lack of association of birth size with polymorphisms of two imprinted genes, *IGF2R* and *GRB10*. *J Ped Endocrinol Metab* 2004, 17:1215-1220.
66. \*McCann JA, \*Xu YQ, \*Frechette R, Guazzarotti R and **Polychronakos C**. The insulin-like growth factor-II receptor gene is associated with type 1 diabetes: evidence of a maternal effect. *J Clin Endocrinol Metab*. 2004, 89(11):5700-6.
67. \*Anjos S, \*Tessier MC and **C Polychronakos**. Association of the *CTLA4* gene with type 1 diabetes: independent effects of two SNPs on the same haplotype block. *J Clin Endocrinol Metab* 2004, 89:5700-6.
68. \*Mitchell J, \*Punthakee Z, Lo B, Bernard B, Chong K, Newman C, Cartier L, Desilets V, Cutz E, Hansen IL, Riley P and **C Polychronakos**. Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gallbladder hypoplasia: A search for the etiology of a new autosomal recessive syndrome. *Diabetologia* 2004, Dec;47(12):2160-7
69. \*Qu H, \*Tessier M-C, Hudson TJ and **Polychronakos C**. Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 Diabetes in a family-based study. *Journal of Medical Genetics*. 2005, 42(3) 266-270.
70. \*Qu H, Bharaj B, Liu XQ, Curtis JA, Newhook LA, Paterson AD, Hudson TJ and **C Polychronakos**. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. *Nature Genetics*. 2005, 37:111-112.
71. \*Anjos S, \*Shao W, \*Marchand L and **C Polychronakos**. Allelic effects on gene regulation at the autoimmunity-predisposing *CTLA4* locus: a re-evaluation of the 3'+6230G>A polymorphism. *Genes and Immunity* 2005, 6(4):305-11.
72. \*Tessier MC, \*Qu HQ, \*Frechette R, Bacot F, \*Grabs R, Taback SP, Lawson ML, Kirsch SE, Hudson TJ and **Polychronakos C**. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? *J Med Genet*. 43:129-32 2006
73. Durinovic-Belló I, \*Jelinek E, Schlosser M, Eiermann T, Boehm BO, Karges W, \*Marchand L and **Polychronakos C**. Class III alleles at the insulin VNTR polymorphism are associated with regulatory T-lymphocyte responses to proinsulin epitopes in HLA-DR4, DQ8 individuals. *Diabetes* 2005 54:S18-S24.
74. \*Qu H, \*Tessier M C, \* Frechette R, Bacot F, **Polychronakos C**. Lack of association of type 1 diabetes with the IL4R gene. *Diabetologia* 49:958-961, 2006.

75. Legault L, **Polychronakos C**. Annual incidence of type 1 diabetes in Quebec between 1989-2000 in children. *Clin Invest Med*. 29:10-3, 2006 .
76. \*Qu H, \*Guo F, Majewski J and **Polychronakos C**. Strand bias of complementary single-nucleotide polymorphisms in transcribed human sequences: evidence for functional effects of synonymous substitutions. *BMC Genomics*. 2006 Aug 17;7:213.
77. \*Palumbo M, \*Levi D, \*Chentoufi AA and **C Polychronakos**. Isolation and Characterization of Proinsulin-producing medullary thymic epithelial cell clones. *Diabetes* 2006, 55(9):2595-601
78. Durinovic-Belló, Rosinger S, Olson JA, Congia M, Ahmad RC, Rickert M, Hamp J, Kalbacher H, Drijfhout JW, Mellins ED, Al Dahouk S, Roep BO, Nepom GT, Kamradt T, Maeurer MJ, Karges W, Boehm BO, Nhan C\*, **Polychronakos C**, McDevitt HO and Sønderstrup G. DRB1\*0401-restricted human T-cell clone, specific for the major proinsulin 73-90 epitope expresses a regulatory T helper 2 phenotype. *Proc Natl Acad Sci USA*. Aug 2006 103(31):11683-8..
79. \*Marchand L, **Polychronakos C**. Evaluation of Polymorphic Splicing in the Mechanism of the Association of the Insulin Gene with Type 1 Diabetes. *Diabetes* 2007 Mar;56(3):709-13.
80. \*Qu H., \*Yang L., Montpetit A., **Polychronakos C**. Genetic control of alternative splicing in the *TAP2* gene: Possible implication in the genetics of type 1 diabetes. *Diabetes* 2007 56:270-275,2007.
81. \*Qu HQ, \*Marchand L, \*Frechette R, Bacot F, \*Lu Y, **Polychronakos C**. No association of type 1 diabetes with a functional polymorphism of the LRAP gene. *Molecular Immunology*. 44:2145-8, 2007.
82. \*Qu HQ and **Polychronakos C**. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. *Diabetes* 2007 Apr;56(4):1174-6.
83. \*Qu HQ, \*Grabs R, \*Marchand L, **Polychronakos C**. The IRF5 Polymorphism in Type 1 Diabetes. *J Med Genet*. 2007 Oct;44(10):670-2.
84. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Prentki M, Posner BI, Balding DJ, Meyre D, **Polychronakos C**, Froguel P. A genome-wide association study identifies novel susceptibility loci for type 2 diabetes mellitus. *Nature* 2007 Feb 22;445(7130):881-5. **I am the corresponding author in this paper.**
85. Hakonarson H, Grant SF, Bradfield JP, \* Marchand L, Kim CE, Glessner JT, Grabs R, Casalunovo T, Taback SP, Frackelton EC, Lawson ML, Robinson LJ, Skraban R, Lu Y, Chiavacci RM, Stanley CA, Kirsch SE, Rapoport EF, Orange JS, Monos DS, Devoto M, \*Qu HQ, **Polychronakos C**. A Genome-Wide Association Study Identifies KIAA0350 as a novel Type1 Diabetes Gene. *Nature* 2007 Aug 2; 448(7153):591-4.
86. \*Qu, H. Polychronakos, C. The TCF7L2 locus and type 1 diabetes. *BMC Med Genet*

2007 8:51.

87. Gutierrez-Aguilar R, Benmezroua Y, Balkau B, Marre M, Helbecque N, Charpentier G, **Polychronakos C**, Sladek R, Froguel P, Neve B. Minor contribution of SMAD7 and KLF10 variants to genetic susceptibility of type 2 diabetes. *Diabetes Metab*. 2007 Nov;33(5):372-378.
88. \*Qu, H., \*Marchand, L., \*Grabs, R., **Polychronakos, C.** The Association between the IFIH1 Locus and type 1 Diabetes. *Diabetologia*. 2008 51:473-5.
89. 89. Hakonarson H, \* Qu HQ, Bradfield JP, \* Marchand L, Kim CE, Glessner JT, \*Grabs R, Casalunovo T, Taback SP, Frackelton EC, Eckert AW, Annaiah K, Lawson ML, Otieno FG, Santa E, Shaner JL, Smith RM, Onyiah CC, Skraban R, Chiavacci RM, Robinson LJ, Stanley CA, Kirsch SE, Devoto M, Monos DS, Grant SF, **Polychronakos C**. A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. *Diabetes* 2008 57:1143-6.
90. \*Qu HQ, \*Marchand L, Szymborski A, \*Grabs R, **Polychronakos C**. The association between type 1 diabetes and the ITPR3 gene polymorphism is due to linkage disequilibrium with HLA. *Genes and Immun*. 2008 9:264-6.
91. \*Qu HQ, Grant SF, Bradfield JP, Kim C, Frackelton E, Hakonarson H, **Polychronakos C**. Association Analysis of the Type 2 Diabetes Loci in Type 1 Diabetes. *Diabetes*. 2008 57:1983-6. PMID: 18426861
92. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, Cavalcanti-Proenca C, Marchand M, hartikainen Al, Sovio U, De Graeve F, Rung J, Vaxillaire M, Tichet J, Marre M, Balkau B, Weill J, Elliott P, Jarvelin Mr, Meyre D, **Polychronakos C**, Dina C, Sladek R, Froguel P. A Polymorphism Within The G6PC2 Gene Is Associated with Fasting Plasma Glucose. *Science* 2008; May 23;320(5879):1085-8. PMID: 18451265
93. Grant SF, Qu HQ, Bradfield JP, \* Marchand L, Kim CE, Glessner JT, \* Grabs R, Taback SP, Frackelton EC, Eckert AW, Annaiah K, Lawson ML, Otieno FG, Santa E, Shaner JL, Smith RM, Skraban R, Imielinski M, Chiavacci RM, Grundmeier RW, Stanley CA, Kirsch SE, Waggott D, Paterson AD; The DCCT/EDIC Research Group, Monos DS, **Polychronakos C**, Hakonarson H. Follow up analysis of genome-wide association data identifies novel loci for type 1 diabetes. *Diabetes*. 2009 Jan;58(1):290-5. Epub 2008 Oct 7. E-pub ahead of print (**co-corresponding author**).PMID: 18840781
94. Meyre D, Delplanque J, Chèvre JC, Lecoeur C, Lobbens S, Gallina S, Durand E, Vatin V, Degraeve F, Proença C, Gaget S, Körner A, Kovacs P, Kiess W, Tichet J, Marre M, Hartikainen AL, Horber F, Potoczna N, Hercberg S, Levy-Marchal C, Pattou F, Heude B, Tauber M, McCarthy MI, Blakemore AI, Montpetit A, **Polychronakos C**, Weill J, Coin LJ, Asher J, Elliott P, Järvelin MR, Visvikis-Siest S, Balkau B, Sladek R, Balding D, Walley A, Dina C, Froguel P. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat Genet*. 2009 Feb;41(2):157-9. PMID: 19151714

95. Bossé Y, Bacot F, Montpetit A, Rung J, Qu HQ, Engert JC, **Polychronakos C**, Hudson TJ, Froguel P, Sladek R, Desrosiers M. Identification of susceptibility genes for complex diseases using pooling-based genome-wide association scans. *Hum Genet.* 2009 Apr;125(3):305-18. Epub 2009 Jan 29. PMID:19184112  
PMID: 19184112
95. H-Q Qu, JP Bradfield, SFA Grant, H Hakonarson, **C Polychronakos** and the Type 1 Diabetes Genetics Consortium. Association of RASGRP1 with type 1 diabetes is revealed by combined follow-up of two genome-wide studies. *J Med Genet* 2009;46:553-554.  
PMID: 19465406
96. Hui-Qi Qu, **Constantin Polychronakos**. The effect of the *MHC* locus on autoantibodies in type 1 diabetes. Accepted for Publication, *J Med Genet* 2009;46:469-471.  
PMID:19429597
97. Qu H, Verlaan DJ, Ge B, Lu Y, Kevin CL, Lam CL, Grabs R, Harmsen E, Hudson TJ, Hakonarson H, Pastinen T, **Polychronakos C**. A Cis- Acting Regulatory Variant in the IL2RA locus. *J Immunol* 2009; Oct 15; 183(8): 5158-62. PMID:19794070 **Cover illustration**
98. Wei Z, Wang K, Qu HQ, Zhang H, Bradfield J, Kim C, Frackleton E, Hou C, Joseph T, Glessner JT, Chiavacci R, Stanley C, Monos D, Grant S, **Polychronakos C**, Hakonarson H. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. *PLoS Genetics* 2009; (October; 5(10))  
PMID:19816555
101. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, Bacot F, Balkau B, Belisle A, Borch-Johnsen K, Charpentier G, Dina C, Durand E, Elliott P, Hadjadj S, Järvelin MR, Laitinen J, Lauritzen T, Marre M, Mazur A, Meyre D, Montpetit A, Pisinger C, Posner B, Poulsen P, Pouta A, Prentki M, Ribel-Madsen R, Ruokonen A, Sandbaek A, Serre D, Tichet J, Vaxillaire M, Wojtaszewski JF, Vaag A, Hansen T, **Polychronakos C**, Pedersen O, Froguel P, Sladek R. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. *Nature Genetics*.2009, 41(10):1110-5
102. Qu HQ Bradfield JP, Grant SFA, Hakonarson H, **Polychronakos C** and the Type 1 Diabetes Genetics Consortium. Remapping the type I diabetes association of the CTLA4 locus. *Genes and Immunity* (2009) 10, S27-S32
103. Steck AK, Baschal EE, Jasinski JM, Boehm BO, Bottini N, Concannon P, Julier C, Morahan G, Noble JA, **Polychronakos C**, She JX and Eisenbarth GS and the Type I Diabetes Genetics Consortium. rs2476601 T allele (R620W) defines high-risk *PTPN22* type I diabetes-associated haplotypes with preliminary evidence for an additional protective haplotype. *Genes Immun* 10: S21-S26; doi:10.1038/gene.2009.87
104. Qu HQ, Bradfield JP, Bélisle A, Grant SFA, Hakonarson H and **Polychronakos C** and the Type I Diabetes Genetics Consortium. The type I diabetes association of the *IL2RA* locus. *Genes Immun* 10: S42-S48; doi:10.1038/gene.2009.90

105. Qu HQ and **Polychronakos C** and the Type I Diabetes Genetics Consortium. Reassessment of the type I diabetes association of the *OAS1* locus. *Genes Immun* 10: S69-S73; doi:10.1038/gene.2009.95
106. Saferali A, Grundberg E, Berlivet S, Beauchemin H, Morcos L, **Polychronakos C**, Pastinen T, Graham J, McNeney B and Naumova AK Cell culture-induced aberrant methylation of the imprinted IG DMR in human lymphoblastoid cell lines. *Epigenetics* 5:1, 1-12; January 1, 2010;
108. Qu HQ, Jacob K, Fatet S, Ge B, Barnett D, Delattre O, Faury D, Montpetit A, Solomon L, Hauser P, Garami M, Bognar L, Hansley Z, Mio R, Farmer JP, Albrecht S, **Polychronakos C**, Hawkins C, Jabado N. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. *Neuro Oncol.* 2010;12:153-63. Epub 2009 Oct 15 (**corresponding author**)
109. Smith SB, Qu HQ\*, Taleb N\*, Kishimoto NY, Scheel DW, Lu Y, Patch AM, Grabs R\*, Wang J, Lynn FC, Miyatsuka T, Mitchell J, Seerke R, Désir J, Eijnden SV, Abramowicz M, Kacet N, Weill J, Renard ME, Gentile M, Hansen I, Dewar K, Hattersley AT, Wang R, Wilson ME, Johnson JD, **Polychronakos C**, German MS. *RFX6* directs islet formation and insulin production in mice and humans. *Nature*. 2010 Feb 11;463(7282):775-80. (**corresponding author, featured in Making the Paper**)
110. Wang K, Baldassano R, Zhang H, Qu HQ, Imielinski M, Kugathasan S, Annese V, Dubinsky M, Rotter JI, Russell RK, Bradfield JP, Sleiman PM, Glessner JT, Walters T, Hou C, Kim C, Frackelton EC, Garris M, Doran J, Romano C, Catassi C, Van Limbergen J, Guthery SL, Denson L, Piccoli D, Silverberg MS, Stanley CA, Monos D, Wilson DC, Griffiths A, Grant SF, Satsangi J, **Polychronakos C**, Hakonarson H. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. *Hum Mol Genet*. 2010 Mar 2. [Epub ahead of print]
111. Qu HQ\*, Bradfield JP, Li Q, Kim C, Frackelton E, Grant SF, Hakonarson H, **Polychronakos C**. In Silico Replication of the Genome-wide Association Results of the Type 1 Diabetes Genetics Consortium. *Hum Mol Genet*. 2010 Apr 8. [Epub ahead of print]

### Ανασκοπήσεις, μονογραφίες, σχολιασμός, κεφάλαια σε βιβλία

1. **C. Polychronakos.** The mannose-6-phosphate/IGF-II receptor. In: *Molecular and Cellular Biology of Insulin-like Growth Factors and Their Receptors*. D. LeRoith, M. Raizada, (eds), Plenum Press, New York, pp. 369-380, 1989.
2. **C. Polychronakos.** Parental imprinting of the genes for IGF-II and its receptor. In: *Advances in Experimental Medicine and Biology*. 189-203, 1994.

3. Furlanetto RW et al.. Guidelines for the use of growth hormone in children with short stature; A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. *J Pediatrics* 127:897--67, 1995.
4. **Polychronakos C.** The Altruistic Medical Researcher. *Annals of the Royal College of Physicians and Surgeons of Canada* 30:483-84, 1997.
5. **Polychronakos C**, Deal C. Insulin IGF II and Insulin Dependent Diabetes Mellitus. *Growth, Genetics and Hormones* Vol. 14(2): 27-31, 1998.
6. **Polychronakos C** and A Pugliese. The Insulin VNTR in the genetics of type 1 diabetes, *Genetics of Diabetes Mellitus*, W.L. Lowe, Jr. (ed.), Kluwer Academic Publishers, 10: 65-77, 2000.
7. **Polychronakos C.** Programmed cell death in the pathogenesis of autoimmune diabetes. *Programmed Cell Death, Volume II, Role in Disease, Pathogenesis and Prevention* Ed. by M.P. Mattson, S. Estus and V.M. Rangnekar. 55-79, 2001 Elsevier Science.
8. **Polychronakos C.** The Human Genome Project: What is in it for the Endocrinologist? International symposium on a Current Review of Pediatric Endocrinology, jointly sponsored by *Serono Symposia USA* and The Lawson Wilkins Pediatric Endocrine Society, July 10-13, 2001, Montreal, Canada, *Proceedings*: pp. 165-173, 2001.
9. **Polychronakos C**, \*Palumbo Ta βλαστοκύτταρα στην θεραπεία του διαβήτη *PENAI*, 18:9-12, 2002
10. **Polychronakos C.** New insights into the genetics of neonatal diabetes. Invited review, *Reviews in Endocrine and Metabolic Disorders*, 4:19-22, 2003.
11. **Polychronakos C.** Impact of the human genome project on Pediatric Endocrinology. Invited review in Hormone Research. *Hormone Research*, 59(2):55-56, 2003.
12. \*Kukuvitis A and **C Polychronakos**. Parental Genomic imprinting in endocrinopathies. Invited review, European Journal of Endocrinology.

13. **Polychronakos C.** \*Punthakee Z. Molecular concepts and techniques in Endocrinology. Invited book chapter in *Pediatric Endocrinology Mechanisms, Manifestations, and Management*, O. Peskovitz, ed. Lippincott, Williams and Wilkins first edition 2004.
14. \*Anjos S, **Polychronakos C.** Mechanisms of genetic susceptibility to type 1 diabetes: beyond HLA. Invited review in *Molecular Genetics and Metabolism Mar*; 81(3):187-95, 2004.
15. **Polychronakos C.** Animal models of spontaneous autoimmune diabetes: notes on their relevance to the human disease. Invited editorial in *Current Diabetes Reports*, 4(2):151-4, 2004.
16. **Polychronakos C.** Early-onset diabetes: tip or iceberg? Invited editorial in *Pediatric Diabetes*. 5: 171-173, 2004
17. Kim MS, **Polychronakos C.** Immunogenetics of Type 1 Diabetes. *Hormone Research*. 2005 Oct 24;64(4):180-188.
18. Nakhla M, **Polychronakos C.** Monogenic and other unusual causes of diabetes mellitus. *Pediatric Clinics of North America*. 2005 Dec;52(6):1637-50.
19. \*Punthakee Z, **Polychronakos C.** Diabetes Mellitus. In *Essential Pediatric Endocrinology and Inborn Errors of Metabolism*. K. Sarafoglou, editor, McGraw-Hill. In press.
20. **Polychronakos C.** Genetic testing in clinical endocrinology. *Hormones* (Athens). 2003 2:201-10.
21. **Polychronakos C.** Genetic variation and health; towards individualized medicine. *Pediatr Endocrinol Rev*. 2004 Aug;1 Suppl 3:540-4.
22. **Polychronakos, C.** New applications of microarray data analysis: integrating genetics with 'Omics'. *Pharmacogenomics*. 2008 Jan;9(1):15-7.
23. **Polychronakos, C.** Common and Rare Alleles as Causes of Complex Phenotypes. *Current Atherosclerosis Reports* 2008 Jun;10(3):194-200.
24. **C. Polychronakos.** What Is New in the Genetics of Type 2 Diabetes. *Med Sci (Paris)*. 2008 Mar;24(3):241-242.1
25. \*Ounissi-Benkalha H, **Polychronakos C.** The molecular genetics of type 1 diabetes. New genes and emerging mechanisms. *Trends Mol Med*. 2008 Jun;14(6):268-75.
26. \*Chentoufi AA, Binder Nr, Berka N, Abunadi T, **Polychronakos C.** Advances in Type 1 Diabetes Associated Tolerance Mechanisms. *Scand J Immunol*. 2008 Jul;68(1):1-11.

27. Makri A, Pissimisis N, Lembessis P, **Polychronakos C**, Koutsilieris M. The kisspeptin KiSS-1/GPR54 system in cancer biology. *Cancer Treat Rev.* 2008 Jun 24.
27. Hui-Qi Qu and Constantin Polychronakos. *The Genetic Basis of Diabetes* in Diabetes in Women, Pathophysiology and Therapy Series: Contemporary Diabetes Tsatsoulis, Agathocles; Wyckoff, Jennifer; Brown, Florence M. (Eds.) 2010, XII, 462 p. 44 illus., 8 in color., Hardcover ISBN: 978-1-60327-249-0

## Περιλήψεις παρουσιάσεων

1. Polychronakos C, Bithieu M, Hamel R, Savoie S, Ducharme JR LH et testosterone plasmatiques B la periode neonatale chez l'agneau. XXI Annual Meeting of the Club de Recherches Cliniques du Quebec. Abstract no. 30, 1979.
2. Hamel R, Polychronakos C, Forest MG, Haour F, Ducharme JR Etude de la sensibilite testiculaire B la periode neonatale chez l'agneau au cours du premier mois de vie. Ibid., Abstract no. 31, 1979.
3. Hamel R, Polychronakos C, Forest MG, Haour F, Charpenet G, Savoie S, Gibb W, Collu R, Ducharme JR. Testicular responsiveness to hCG in the lamb during the first month of life. 62nd Annual Meeting of the Endocrine Society, Washington, D.C., June, 1980.
4. Polychronakos C. Bone and hormonal maturation in the young child. Participation in a round table on growth at the XVI International Congress of the World Organization for Preschool Education, Quebec City, July, 1980.
5. Polychronakos C, Ruggere D, Posner B, Guyda H. Studies on the effect of erythrocyte age on their insulin receptor. The Canadian Society for Clinical Investigation, Toronto, September 1981. Abstract published in Clinical Investigative Medicine 4 (2): 14B.
6. Polychronakos C, Guyda HJ, Posner BI. Receptors for the insulin-like growth factors are increased in young human erythrocytes. The Canadian Society for Clinical Investigation, Quebec City, 1982. Abstract in Clinical Investigative Medicine 5 (2/3): 15B.
7. Polychronakos C, Burnstein R, Posner BI, MacDougall JD, Guyda HJ, Toews CJ. Acute decrease in erythrocyte insulin binding with increased insulin resistance in detrained athletes. The Canadian Society for Clinical Investigation, Quebec City, 1982. Abstract in Clinical Investigative Medicine 5 (2/3): 38B.
8. Polychronakos C, Guyda HJ, Posner BI. Influence de l'age cellulaire sur les recepteurs aux somatomedines (IGF) des globules rouges. XIV Meeting of the Club de Recherches Cliniques du Quebec, 1982. Abstract in Union Medicale du Canada, Suppl. to Vol. III.
9. \*Costigan DC, Polychronakos C, Posner BI, Guyda HJ. Increase in specific binding of erythrocyte receptors for insulin-like growth factors 2 in hypopituitary children treated with growth hormone. Annual Meeting of the Canadian Society of Clinical Investigation, Montreal, 1984. Clinical Investigative Medicine 7 (Suppl. 2): 41.
10. Polychronakos C, Guyda HJ, Posner BI. Insulin-like growth factor receptor modulation in compensatory kidney growth. Annual Meeting of the Canadian Society for Clinical Investigation, Montreal, 1984. Clinical Investigative Medicine 7 (Suppl. 2): 45.
11. Polychronakos C, Guyda HJ. Transient growth deceleration in normal short children. 1985 Annual Meeting of the American Pediatric Society. Pediatric Research 19: 191A, #482.
12. Polychronakos C, Guyda HJ. Increase of insulin like growth factor 2 receptor binding to membrane from rat thyroids undergoing propyl-hiuracil-induced hyperplasia. 1985 Annual Meeting of the Endocrine Society.
13. Polychronakos C, Fantus IG. Tyrosine kinase is enhanced in thyroid cytosol during PTU-induced hyperplasia. 1986 Annual Meeting of CSCSI, Toronto. Clinical and Investigative Medicine, Suppl., vol. 9(3), abstract #C-244.

14. Polychronakos C, Fantus IG. Tyrosine kinase activity in the rat thyroid during propylthiouracil-induced hyperplasia. 1987 Annual Meeting of the Endocrine Society.
15. Barenton B, Guyda HJ, Goodyer CG, Polychronakos C, Posner BI. Lack of IGF-I binding to type II IGF receptors in hypo-physectomized rat liver and evidence for a type-I like IGF receptor with high affinity for IGF-II but not insulin in human placenta. 1987 Annual Meeting of the Endocrine Society.
16. Polychronakos C, Piscina R, Guyda H. Mannose-6-phosphate increases the affinity of the insulin-like growth factor II for its receptor on rat liver microsomes. 1988 Annual Meeting of the Endocrine Society.
17. Polychronakos C. Interactions of IGF-II and mannose-6-phosphate on their common receptor: effects on binding and endocytosis. Second International Conference of Anticancer Research, Athens, Greece, 1988.
18. Polychronakos C, Pollak MN, Guyda H. Plasma levels of growth hormone and IGF-I in cancer patients treated with a long-acting somatostatin analog (SMS 201-995). Second International Conference of Anticancer Research, Athens, Greece, 1988.
19. Pollak M, Polychronakos C, Richard M. Insulin-like growth factor-I (IGF-I) receptors of human osteosarcoma cells: characterization and potential significance. ASCO Annual Meeting, San Francisco, 1989.
20. Chan A, Teshima I, Polychronakos C, Holland FJ, Weksberg R. Analysis of a deletion of chromosome 12q in a patient with short stature. Annual Meeting of the Royal College of Physicians, Toronto, 1990.
21. Weksberg R, Feigenbaum A, Australie K, Polychronakos C. Insulin-like growth factor (2) - serum levels are normal in patients with Beckwith-Wiedemann Syndrome. American Society of Human Genetics, October 1990.
22. Pollak M, Polychronakos C, Guyda H, Malaab S, Goodyer C, Margolese R. Tamoxifen decreases serum IGF-I levels in breast cancer patients and alters GH secretion by cultured pituitary cells. Second International Symposium on Insulin-like Growth Factors / Somatomedins, San Francisco, California, January 1991.
23. Pollak M, Polychronakos C, Malaab S, Goodyer C. Effects of tamoxifen on the growth hormone (GH) insulin-like growth factor (IGF-I) axis. American Society of Clinical Oncology, Houston, Texas, May 19-21, 1991.
24. Treacy E, Vekemans M, Blaichman S, Lavallie S, Polychronakos C, Xu Y, Knoll J, Lalande M, Der Kaloustian V. De novo translocation between chromosomes 6 and 15 and detailed mapping of IGF-II/Mannose-6- phosphate receptor. 8th International Congress of Human Genetics, Washington, D.C., 1991.
25. \*Giannoukakis N., Polychronakos C. Insulin stimulates degradation of sulphated proteoglycans in the extracellular matrix of rat hepatoma cells. Annual Meeting of the Endocrine Society, Washington 1991.
26. Polychronakos C. A soluble form of the mannose-6-phosphate/IGF-II receptor in human amniotic fluid. Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Quebec City, September 19-23, 1991.
27. Koutsilieris M, Frenette G, Janthly U, and Polychronakos C. Paracrine interactions between PA-III rat prostate adenocarcinoma cells and UMR-106 rat osteoblasts. Annual Meeting of the Endocrine Society, San Antonio, Texas, June 1992.
28. Polychronakos C, Deal C, Xu Y, Giannoukakis N. Studies on the genomic imprinting of the human genes for the insulin-like growth factor II (IGF-II) and its receptor. American Society of Human Genetics, 1992.
29. Stalker HJ, Byers P, Phillips JA, Cogan JD, Polychronakos C, Sedun K, and Der Kaloustian VM. Coexistence of osteogenesis imperfecta type I and hypopituitarism - a non random association or a separate entity? American Society of Human Genetics, 1992.
30. \*Xu Y, Giannoukakis N, Deal C, Polychronakos C. Empreinte parentale du gène pour le insulin-like growth factor II (IGF-II) mais pas pour son récepteur dans le placenta humain. 34e Congrès de la Fédération des Gynéco-Obstétriciens de langue Française, Québec 1992.
31. Koutsilieris M, Frenette G, Lazure C, Breton N, Lavergne E, Govindan MV, Polychronakos C. Rat urokinase-type plasminogen activator purified from PA-III prostate cancer cells stimulates osteoblasts via an IGF-I dependent mechanism. Annual Meeting of The Endocrine Society, 1993.

32. Deal C, Polychronakos C and Paquette J. Bi-allelic expression of the gene for hIGFBP-3 in term placenta. International IGF Meeting in Sydney, Australia, 1994.
33. Polychronakos C, Kukuvitis A, Giannoukakis N, Colle E. Parental imprinting at the INS-IGF2 diabetes susceptibility locus. Annual Meeting of the Endocrine Society, Abstract #1247, page 512, 1994.
34. Paquette J, Ledru E, Polychronakos C, Deal C. Loss of genomic imprinting at the IGF2 locus in human placental fibroblast cultures following serial passaging. Annual Meeting of the Endocrine Society, Abstract #1476, page 569, 1994.
35. Polychronakos C, Xu Y, Grundy P. Aberrant imprinting of the *IGF2R* gene in Wilms tumor. European Society of Human Genetics 26th Annual Meeting, 1994.
36. \*Kukuvitis A, Giannoukakis N, Arbour L, Woods S, Polychronakos C. Autosomal dominant neonatal hyperinsulinemia. Abstract #1115, Royal College of Physicians and Surgeons Annual Meeting, Toronto, 1994.
37. \*Xu Y, Polychronakos C. A cis-acting locus determines the polymorphic parental imprinting of the human IGF2R gene. Abstract #783, American Society of Human Genetics Annual Meeting, October 1994.
38. \*Giannoukakis N, Deal C, Kukuvitis A, Rouleau G, Polychronakos C. Variability of IGF2 imprinting in blood, among human individuals, correlates with H19 expression. Genomic Imprinting International Symposium, Florence, Italy, 1994.
39. \*Kukuvitis A, Giannoukakis N, Arbour L, Woods S, Polychronakos C. Candidate genes for the autosomal dominant form of neonatal hyper-insulinemia. The Endocrine Society, Washington D.C., June, 1995.
40. Polychronakos C, Vafiadis P, Giannoukakis N, Colle E. Imprinting and genotype-dependent gene expression at the IDDM2 locus in pancreas and lymphocytes, 14th Immunology of Diabetes Workshop, Orvieto, Italy, October 1995.
41. Vafiadis P., Grabs R., Ounissi-Benkhal H., Goodyer C.G. & Polychronakos C. Class III *INS*-VNTR alleles associated with silencing of insulin in the thymus strongly predispose to diabetes. American Diabetes Association meeting, San Diego, June 1996.
42. \*Giannoukakis N, Vafiadis P, Polychronakos C, Paquette J and Deal C. Association between *IGF2* expression and VNTR class at the *INS* 5' in human placenta, 10th International Congress of Endocrinology, San Francisco, CA, June 1996.
43. Koutsilieris M, Sourla A, Polychronakos C, Zeng WR, Nepveu A, Kukuvitis A, Naud F and Maheux R. Plasminogen activator inhibitor-1 (PAI-1) mRNA expression and molecular evidence for del(7)(q22) in a subgroup of uterine leiomyomas, 10th International Congress of Endocrinology, San Francisco, CA, June 1996.
44. \*Vafiadis P, Grabs R, Polychronakos C. *IDDM2* allele effects on *IGF2* mRNA levels in the major tissues implicated in type I diabetes autoimmunity. 16th IDF Congress, Helsinki, 1997.
45. \*Kukuvitis A, Colle E, \*Xu Y, Polychronakos C. Evidence against the insulin-like growth factor II receptor gene (*IGF2R*) as a diabetes susceptibility gene. 10th International Congress of Endocrinology, San Francisco, CA, June 1996.
46. Bennett ST, Wilson AJ, Esposito L, Cucca F, Polychronakos C, Nistico L, et al. Allelic variation at the insulin gene minisatellite locus and parent-of-origin effects in human disease. Chromosome 11 Symposium, Niagara-On-The-Lake, May 1996.
47. \*Barnes R, Grabs R and Polychronakos C. A *CTLA4* polymorphism affects lymphocyte mRNA levels but is not associated with type I diabetes in a Canadian dataset. 16th IDF Congress, Helsinki, 1997.
48. \*Xu Y, Grundy P, Polychronakos C. Imprinting of the IGF-II receptor gene in Wilms tumor: epigenetic changes and possible etiologic significance. The Joint meeting of the European Society of Pediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Stockholm, 1997 (\$1,000 US travel Grant to Y.X.).
49. Ducharme FM, Polychronakos C, Glorieux F, Chabot G, Mazer B. Impact on bone density and HPA axis of frequent

- short courses (bursts) of oral corticosteroids in the treatment of acute pediatric asthma. Ambulatory Pediatric Association, 1997
50. **Polychronakos C.** *Class III INS VNTR* alleles associated with silencing of thymic *INS* expression strongly predispose to type 1 diabetes. The 59th Annual Scientific Meetings and Sessions, American Diabetes Association Convention, San Diego, CA, June 19-22, 1999.
51. Croteau S, **Polychronakos C**, Naumova A. Loss of imprinting of *H19*, but not *Igf2* in early mouse embryos. Cold Spring Harbor Symposium, 2000.
52. **C Polychronakos**, \*P Vafiadis, \*A Alami-Chentoufi and \*M Rousseau. The IDDM2 diabetes susceptibility locus modulates human insulin – specific T-cell repertoire Abstract #81 5th Immunology of Diabetes Society Congress, Chennai, India, February 2001. Poster discussion (poster and slides).
53. Paquette J, Ledru E, Strange K, Emerman J, **Polychronakos C** and C Deal. Polymorphic relaxation of *IGF2*: a marker for breast cancer susceptibility? 2nd Scientific Conference, sponsored by Canadian Breast Cancer Research Initiative, Québec City, Québec, May 3-5, 2001. Oral presentation
54. \*Jennifer McCann, \*Yongqin Xu, Constantin **Polychronakos**. IGF2R as a candidate gene for autoimmune diabetes. Pediatric Endocrinology 2001, Montréal 2001. Oral presentation.
55. \*Aziz Alami-Chentoufi and Constantin **Polychronakos** Thymic Insulin Expression Levels Determine Insulin-Specific Autoreactive T-cell Selection: Mechanism by which the *IDDM2* Locus Predisposes to Autoimmune Diabetes. Abstract #4-664 11th International Congress of Immunology, Stockholm, July 2001. Oral presentation.
56. \*Anjos S, Nguyen A, \*Ounissi-Benkalha H, & **Polychronakos C**. A diabetes-associated polymorphic variant of the Cytotoxic T-Lymphocyte Antigen-4 (CTL-4) alters translocation to the endoplasmic reticulum. Abstract #5-443, 11th International Congress of Immunology, Stockholm, July 2001. Oral presentation.
57. \*Samara R. Zavalkoff and Constantin **Polychronakos** Evaluation of conventional blood glucose monitoring as an indicator of integrated glucose values using a continuous subcutaneous sensor. Meeting of the Canadian Society of Endocrinology and Metabolism, Vancouver 2002. Oral presentation.
58. **C. Polychronakos, C.A. Marquette, A. Macanovic, I. Lawrence and M.F. Lawrence.** Oligonucleotide hybridization: detection and Tm estimation based on electrochemical impedance measurements on Si/SiO<sub>2</sub> chips: potential for hybridization-based SNP genotyping. 5th International Meeting On Single Nucleotide Polymorphisms and Complex Genome Analysis, Reykjavik, Iceland October 2002. Poster
59. \*O. Leloup, A. Macanovic, M.F. Lawrence, **C. Polychronakos**. Continuous glucose quantification by electrochemical impedance measurements on a concanavalin A-Si/SiO<sub>2</sub> substrate. Second Annual Diabetes Technology Meeting, October 2002 Atlanta. Poster.
60. \*Palumbo M, Chentoufi A, Grabs RM, **Polychronakos C**. Insulin expression in thymus epithelial cells of Hassall's corpuscles. American Diabetes Association meeting, New Orleans 2003. Oral presentation.
61. Webster JD, Dean HJ, Anjos S, **Polychronakos C**, Sellers EAC, Taback SP. Genetics and outcomes of Graves' disease in youth. 2004 Pediatric Academic Societies' Annual Meeting in San Francisco, CA. May 1-4, 2004. Oral presentation.
62. \*Qu H, **Polychronakos C**. A function-based approach to genome-wide association search for type 1 diabetes susceptibility loci. 12th International Congress of Immunology, 2004, accepted for oral presentation with travel award.
63. \*Anjos S, **Polychronakos C**. Association of the CTLA4 Gene with Type 1 Diabetes: Opposing Effects of Two SNPs on the Same Haplotype Block. 12th International Congress of Immunology, 2004, accepted for oral presentation.
64. \*Palumbo M, **Polychronakos C**. Isolation and Culturing of Proinsulin Expressing Thymic Epithelial Cells. 12th International Congress of Immunology, 2004, accepted for oral presentation.
65. \*Qu, H, and **C Polychronakos**. The effect of coding synonymous and 3' UTR SNPs on mRNA secondary structure.

The Human Genome Variation Society: Possible Future Directions? Toronto, 2004.

66. \*Qu H, **Polychronakos C**. Genome-wide analysis of strand asymmetry of complementary single-nucleotide polymorphisms in coding human sequences. VIII Symposium on Mutation Detection, *Human Genome Organization*, Santorini, Greece, May 2005. Oral presentation
67. **Polychronakos C**, Sladek R, Froguel P. A genome-wide association study of type 2 diabetes susceptibility. *Human Genome Variation Society*, New Orleans 2006 (satellite of ASHG meeting). Oral presentation.
68. Du X\*, **Polychronakos C**. Graded overexpression of ZAC inhibits insulin release in the Ins-1 b-cell line. *American Diabetes Association* 2006 annual meeting, scientific sessions, Washington DC. Oral presentation.
69. Levi\*, D., Palumbo\*, M., Polychronakos, C. Regulation of Insulin Expression in Thymic Epithelial Cells. Federation of Clinical Immunology Societies. San Diego, June 2007
70. Rocheleau\*, G., **Polychronakos, C.**, Sladek, R., A Genome-wide association study identifies novel risk loci for type 2 diabetes: statistical issues. *2007 Annual Canadian Genetic Epidemiology and Statistical Genetics meeting* . Toronto. (Ghislain Rocheleau won the first prize for post-doc abstract at that meeting)
71. R. Sladek, L. Shen, D. Meyre, G. Rocheleau\*, C. Dina, J. Rung, L. Shen, A. Mazur, **C. Polychronakos**, DJ Balding, P. Froguel. A two-Stage genome-wide association study for type 2 diabetes. October 2007. ASHG Session 58.
72. A case of neonatal diabetes, cardiopathy and pancreatic exocrine deficiency. P. Olivier, M. Gonthier, G. Mitchell, **C. Polychronakos**. Pediatric Endocrinology, CDA, Vancouver, October 2007.
73. **Polychronakos C**. Qu HQ\*. Effets Fondateurs et la Génétique des Phénotypes Complexes : Un Échantillonage de la Population Québécoise. Les 7ièmes journées génétiques du Réseau de Médecine génétique appliquée. Hotel Loews. Quebec. May 2008.
74. Bossé Y, Bacot F, Montpetit A, Rung J, Qu HQ\*, **Polychronakos C**, Hudson TJ, Froguel P, Sladek R, Desrosiers M. Identification of susceptibility genes for complex diseases using pooling-based genome-wide association scans. Poster presentation at the 58th annual meeting of the American Society of Human Genetics. November 11-15, 2008, Philadelphia, PA, USA. (Poster presentation)
75. Qu, HQ\*, Bradfield JP, Verlaan DJ, Bélisle A, Ge B, Lu Y, Lam C LK, Marchand L\*, Harmsen E, Hudson T, Pastinen T, Grant S FA, Hakonarson H, **Polychronakos C**. The type 1 diabetes association of the *IL2RA* locus and the cis-acting regulation of gene expression The Analytic Results meeting of the Type 1 Diabetes Genetics Consortium (T1DGC). Washington DC. October 21-23, 2008.
76. **Qu HQ\***, Patch AM, Taleb N, Lu Y, Grabs R, Mitchell J, Rilley P, Hattersley AT, **Polychronakos C. (Corresponding Author)** The application of high-density genotyping microarrays in a rare autosomal recessive syndrome of neonatal diabetes A Satellite meeting to the American Society of Human Genetics Annual Meeting. Philadelphia. 11th November 2008.
77. Hui-Qi Qu\*, Struan F.A. Grant, Jonathan P. Bradfield, Luc Marchand, Cecilia E. Kim, Joseph T. Glessner, Rosemarie Grabs\*, Shayne P. Taback, Edward C. Frackelton, Andrew W. Eckert, Kiran Annaiah, Margaret L. Lawson, F. George Otieno, Erin Santa, Julie L. Shaner, Ryan M. Smith, Robert Skraban, Marcin Imielinski, Rosetta M. Chiavacci, Robert W. Grundmeier, Charles A. Stanley, Susan E. Kirsch, Daryl Waggott, Andrew D. Paterson, The DCCT/EDIC Research Group†, Dimitri S. Monos, Hakon Hakonarson, and **Constantin Polychronakos**. A novel type 1 diabetes locus identified by the full stage two of a genome-wide association study The Analytic Results meeting of the Type 1 Diabetes Genetics Consortium (T1DGC). Washington DC. October 21-23, 2008.
78. Hui-Qi Qu\*, **Constantin Polychronakos**(Corresponding author). The *MHC* genes and autoantibodies in type 1 diabetes The Analytic Results meeting of the Type 1 Diabetes Genetics Consortium (T1DGC). Washington DC. October 21-23, 2008.
79. Taleb, N, Hui-Qi Qu, Riley P, Mitchell J, Polychronakos C. Homozygosity mapping and Identification of the Gene Responsible for Neonatal Diabetes with Intestinal atresia. CPEG 2009, February 2009. Ottawa, Ontario.

80. St-Jean J., Ounissi H., Polychronakos C. Screening for Molecular Determinants of Thymic Insulin Expression with Yeast one-Hybrid Technology. American Diabetes Association's 69<sup>th</sup> Scientific Sessions. June 5-9, 2009. New Orleans
81. Zouk H., Polychronakos C. Study of Transcriptional Effects in cis at the IFIH1 locus. American Diabetes Association's 69<sup>th</sup> Scientific Sessions. June 5-9, 2009. New Orleans.
82. C. Polychronakos. Screening for Molecular Determinants of Thymic Insulin Expression with Yeast One-Hybrid Technology. 69<sup>th</sup> Scientific Sessions. ADA. New Orleans. LA. June 2009
83. Nadine Taleb<sup>1</sup>, HuiQi Qu<sup>1</sup>, Yang Lu<sup>1</sup>, Arif Jetha<sup>2</sup>, Stuart B. Smith<sup>3</sup>, Ann-Marie Patch<sup>4</sup>, Rosemary Grabs<sup>1</sup>, John Mitchell<sup>1</sup>, Renian Wang<sup>5</sup>, Steven Paraskevas<sup>2</sup>, Ken Dewar<sup>6</sup>, Andrew T Hattersley<sup>4</sup>, Michael S. German<sup>3</sup>, Constantin Polychronakos<sup>1</sup>. *RFX6*: A novel gene necessary for the development of the endocrine pancreas. MDRC. January 2010

## **Καλυτεχνήματα**

Εξώφυλλο του *Nature Genetics*, Σεπτέμβρης 2005 <http://www.nature.com/ng/journal/v37/n9/covers/index.html>  
Εξώφυλλο του , *Jounral of Immunology*, 15 Οκτώβρη 2009  
Εξώφυλλα του , *Journal of Medical Genetics*, Φεβρουάριος και Απρίλιος 2010